Bioymifi was the first DR5 activator reported in 2013, and it could bind directly to DR5 to activate the caspase 8-induced apoptosis signaling pathway, leading to human glioblastoma (T98G) cells apoptosis (Wang et al., 2013). This evidence concerns the gene CASP8 and glioblastoma.